NeoGenomics (NEO) 44th Annual J.P. Morgan Healthcare Conference summary

Strategic vision and market positioning

• Focused exclusively on oncology diagnostics, leveraging hematology leadership to expand into solid tumor therapy selection and MRD, with over 25% hematology market share and a comprehensive test menu.

• Targeting community settings, where 80% of cancer patients are treated, to deliver NCI-level care locally and differentiate from larger labs.

• Three strategic pillars: expand into solid tumor therapy selection and MRD, evolve offerings for community providers, and make targeted investments for growth and margin expansion.

• Over 4,000 ordering accounts and 15% YoY growth in physicians ordering five or more tests, with significant opportunity to expand provider base.

• Mission centers on improving patient care and becoming the leading provider of comprehensive cancer testing and solutions.

Product innovation and launches

• PanTracer family, including tissue and liquid biopsy, has doubled test volumes year-over-year and fills key portfolio gaps for providers.

• RaDaR ST MRD test launching in Q1, targeting a $20B+ market, with two indications approved and two more submitted for reimbursement.

• Five new products launched in 2023 are projected to contribute ~24% of 2025 clinical revenue.

• Next-generation whole genome MRD assay in development, with clinical launch targeted as early as 2028.

• Favorable reimbursement decisions and multiple patents support new product launches.

Community oncology and customer engagement

• 80% of cancer patients receive care in the community setting, with precision oncology enabled comparable to major cancer centers.

• Sales team expansion accelerates penetration among community oncologists, with increased ordering and headcount from 2023 to 2025.

• High Net Promoter Score (78) reflects strong physician satisfaction, driven by ease of ordering, report simplicity, and comprehensive test menu.

• Targeted investments aim to drive top-line growth and margin expansion in the community setting.